SiegelJA, StabinMG, SharkeyRM. Renal dosimetry in peptide radionuclide receptor therapy. Cancer Biother Radiopharm, 2010; 25:581.
2.
BouchetLG, BolchWE, BlancoHPet al.MIRD Pamphlet No. 19: Absorbed fractions and radionuclide S values for six age-dependent multiregion models of the kidney. J Nucl Med, 2003; 44:1113.
3.
WesselsBW, KonijnenbergMW, DaleRGet al.MIRD Pamphlet No. 20: The effect of model assumptions on kidney dosimetry and response-implications for radionuclide therapy. J Nucl Med, 2008; 49:1884.
4.
BaroneR, Borson-ChazotF, ValkemaRet al.Patient-specific dosimetry in predicting renal toxicity with 90Y-DOTATOC: Relevance of kidney volume and dose rate in finding a dose-effect relationship. J Nucl Med, 2005; 46,Suppl:99S.
5.
BodeiL, CremonesiM, FerrariMet al.Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors. Eur J Nucl Med Mol Imaging, 2008; 35:1847.
6.
StabinMG. MIRDOSE: Personal computer software for internal dose assessment in nuclear medicine. J Nucl Med, 1996; 37:538.
7.
StabinMG, SparksRB, CroweE. OLINDA/EXM: The second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med, 2005; 46:1023.
8.
BurmanC, KutcherGJ, EmamiBet al.Fitting of normal tissue tolerance data to an analytic function. Int J Radiat Oncol Biol Phys, 1991; 21:123.
O'DonoghueJ. Relevance of external beam dose-response relationships to kidney toxicity associated with radionuclide therapy. Cancer Biother Radiopharm, 2004; 19:378.
NiemierkoA, GoiteinM. Dose-volume distributions: A new approach to dose-volume histograms in three-dimensional treatment planning. Med Phys, 1994; 21:3.
